Related references
Note: Only part of the references are listed.Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
Elodie Odore et al.
CLINICAL PHARMACOKINETICS (2016)
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
R. H. Prabhala et al.
LEUKEMIA (2016)
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
R. Gopalakrishnan et al.
ONCOGENE (2016)
Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300
Jonathan H. Shrimp et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Sarah Picaud et al.
CANCER RESEARCH (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Camille Guillerey et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells
Alessandra Zingoni et al.
JOURNAL OF IMMUNOLOGY (2015)
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E. Morelli et al.
LEUKEMIA (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
C. C. Bjorklund et al.
BLOOD CANCER JOURNAL (2015)
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Lei-lei Fu et al.
ONCOTARGET (2015)
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
Cinzia Fionda et al.
ONCOTARGET (2015)
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
Cinzia Fionda et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
MicroRNAs in Cancer
Gianpiero Di Leva et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction
S. Meng et al.
JOURNAL OF DENTAL RESEARCH (2014)
Strategies for modern biomarker and drug development in oncology
Alan D. Smith et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1
Alessandra Soriani et al.
JOURNAL OF IMMUNOLOGY (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
Francois Lamoureux et al.
NATURE COMMUNICATIONS (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2013)
Diverse functions of miR-125 family in different cell contexts
Yu-Meng Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity
Yujie Liu et al.
NATURE MEDICINE (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
Anja Heinemann et al.
CANCER RESEARCH (2012)
Small-Molecule Inhibition of BRDT for Male Contraception
Martin M. Matzuk et al.
CELL (2012)
The role of natural killer cells in immunity against multiple myeloma
James Godfrey et al.
LEUKEMIA & LYMPHOMA (2012)
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors
Hozefa S. Bandukwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
MicroRNA-125b Potentiates Macrophage Activation
Aadel A. Chaudhuri et al.
JOURNAL OF IMMUNOLOGY (2011)
Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Frederic R. Santer et al.
MOLECULAR CANCER THERAPEUTICS (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor
Erin M. Bowers et al.
CHEMISTRY & BIOLOGY (2010)
Chemical Inducers of Targeted Protein Degradation
Kanak Raina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
IRF4: Immunity. Malignancy! Therapy?
Arthur L. Shaffer et al.
CLINICAL CANCER RESEARCH (2009)
Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2009)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Noam Stern-Ginossar et al.
NATURE IMMUNOLOGY (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Widespread microRNA repression by Myc contributes to tumorigenesis
Tsung-Cheng Chang et al.
NATURE GENETICS (2008)
p300 is required for orderly G1/S transition in human cancer cells
N. G. Iyer et al.
ONCOGENE (2007)
Active repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory factor-4
K Yoshida et al.
INTERNATIONAL IMMUNOLOGY (2005)
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells
YT Bryceson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone et al.
BLOOD (2005)
Chemical approaches to controlling intracellular protein degradation
JS Schneekloth et al.
CHEMBIOCHEM (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Chemical genetic control of protein levels: Selective in vivo targeted degradation
JS Schneekloth et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
The role of IRF-4 in transcriptional regulation
S Marecki et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2002)
CBP/p300 histone acetyl-transferase activity is important for the G1/S transition
S Ait-Si-Ali et al.
ONCOGENE (2000)
Share Paper
